Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of mosunetuzumab + lenalidomide vs rituximab + lenalidomide in follicular lymphoma
jRCT2041210051Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of mosunetuzumab, lenalidomide and rituximab in follicular lymphoma (FL) (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Lugano 2014 response criteria. Started Oct 2021; status: active, not recruiting.
02
Drugs
mosunetuzumablenalidomiderituximab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT2041210051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210051.